Compare PFSI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFSI | TNGX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.5B |
| IPO Year | 2018 | 2020 |
| Metric | PFSI | TNGX |
|---|---|---|
| Price | $75.41 | $27.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $128.11 | $21.78 |
| AVG Volume (30 Days) | 512.2K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 59.25 | 26.89 |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $984,629,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.96 | N/A |
| P/E Ratio | $49.64 | ★ N/A |
| Revenue Growth | 3.05 | ★ 48.29 |
| 52 Week Low | $71.68 | $6.21 |
| 52 Week High | $160.36 | $34.39 |
| Indicator | PFSI | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 46.30 |
| Support Level | N/A | $19.74 |
| Resistance Level | $87.40 | $28.41 |
| Average True Range (ATR) | 2.66 | 1.59 |
| MACD | -0.77 | -0.32 |
| Stochastic Oscillator | 23.42 | 31.58 |
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.